SomnoMed Financial Statements From 2010 to 2024

SOMNF Stock  USD 0.17  0.01  5.56%   
SomnoMed financial statements provide useful quarterly and yearly information to potential SomnoMed Limited investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on SomnoMed financial statements helps investors assess SomnoMed's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting SomnoMed's valuation are summarized below:
SomnoMed Limited does not presently have any fundamental trend indicators for analysis.
Check SomnoMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SomnoMed's main balance sheet or income statement drivers, such as , as well as many indicators such as . SomnoMed financial statements analysis is a perfect complement when working with SomnoMed Valuation or Volatility modules.
  
This module can also supplement various SomnoMed Technical models . Check out the analysis of SomnoMed Correlation against competitors.

SomnoMed Limited Company Return On Equity Analysis

SomnoMed's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current SomnoMed Return On Equity

    
  -0.15  
Most of SomnoMed's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SomnoMed Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, SomnoMed Limited has a Return On Equity of -0.1477. This is 99.38% lower than that of the Healthcare sector and 98.31% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 52.35% lower than that of the firm.

SomnoMed Limited Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining SomnoMed's current stock value. Our valuation model uses many indicators to compare SomnoMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SomnoMed competition to find correlations between indicators driving SomnoMed's intrinsic value. More Info.
SomnoMed Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SomnoMed's earnings, one of the primary drivers of an investment's value.

About SomnoMed Financial Statements

SomnoMed stakeholders use historical fundamental indicators, such as SomnoMed's revenue or net income, to determine how well the company is positioned to perform in the future. Although SomnoMed investors may analyze each financial statement separately, they are all interrelated. For example, changes in SomnoMed's assets and liabilities are reflected in the revenues and expenses on SomnoMed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in SomnoMed Limited. Please read more on our technical analysis and fundamental analysis pages.
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia. Somnomed operates under Medical Devices classification in the United States and is traded on OTC Exchange.

Currently Active Assets on Macroaxis

Other Information on Investing in SomnoMed Pink Sheet

SomnoMed financial ratios help investors to determine whether SomnoMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SomnoMed with respect to the benefits of owning SomnoMed security.